Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342966 · ClinicalTrials.gov registry record
Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 34
- Enrollment target
NCT00342966: Completed study, sponsored by National Cancer Institute (NCI).
NCT00342966 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00342966 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
The chemopreventive efficacy of Se was tested in a 10-year human intervention trial; total and lung cancer mortality, total cancer incidence, colorectal cancer and prostate cancer incidence decreased. This study is designed to compare, via stable isotope tracer studies the kinetics of inorganic and organic Se before and following two years of oral supplementation with L-selenomethionine, to measure forms of Se in the plasma (extracellular Se-dependent glutathione peroxidase \[GSHPx\], selenoprotein-P \[SeP\], albumin-bound Se \[AlbSe\] and nonprotein-bound low molecular weight \[LMWSe\] fractions), and to determine the effects of supplementation on the ecology of the hindgut microflora. The forms of Se were chosen to resemble the metabolism of the principal forms of Se in mixed American diets. Sodium selenite, an inorganic form, is metabolized by reduction to selenide which is then either used in the co-translational synthesis of SeCys in specific Se-containing proteins (e.g., glutathione peroxidases, diodinases, selenoproteins P and W), or is converted to methylated excretion products; in this sense it resembles the food form selenocysteine (SeCys) which is metabolized to the selenide level. Selenomethionine (SeMet), an organic form, is a major form of Se in many foods, particularly those of plan origin. In addition to being metabolized to selenide, SeMet also enters the metabolic protein pool by competing with the sulfur-containing amino acid, methionine. A study is proposed to assess the impact of selenium (Se) supplementation on its metabolism in humans. A pilot study will be conducted to test recruitment strategies and sample collection, preparation and analysis and to assess the detectability of two stable isotopes given together. Four subjects will receive two 300 ug oral doses consisting of 150 ug of the stable isotope 76Se as selenite and 150 ug of the stable isotope 74Se as selenomethionine on study days one and twelve. Subjects will be followed for six w
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 1999-06-14 |
| Est. Completion | 2010-07-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00342966
The ClinicalTrials.gov registry entry for NCT00342966 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00342966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00342966 about?
NCT00342966 is a clinical study titled "Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation". The chemopreventive efficacy of Se was tested in a 10-year human intervention trial; total and lung cancer mortality, total cancer incidence, colorectal cancer and prostate cancer incidence decreased. This study is designed to compare, via stable isotope tracer studies the kinetics of inorganic and ...
What is the current status of trial NCT00342966?
This trial is currently completed. The enrollment target is 34 participants. The study started on 1999-06-14. Estimated completion is 2010-07-23.
Who is sponsoring clinical trial NCT00342966?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.